The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2023 to 2030. Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who have treated in the office sitting&sedentary lifestyle. It typically causes burning pain, paresthesias& numbness in a stocking-glove pattern that progress from the feet & hands. Healthcare should carefully consider the patient's goal, functional status & potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the two types of medications approved by the U.S. Food and Drug Administration for treating this disorder.

Peripheral Treatment trends the market

The treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors&Opioids. The medicines inhaled in this treatment costs about a range of 8$ - 560$. They also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, Diarrhea, anxiety, vomiting,Somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %. Various treatments for Painful Diabetic Neuropathy but the most effective & efficient is the peripheral treatment. 

Increasing Prevalence Remains the Key Impeder

Diabetes has become one of the largest global health care diseases of the 21 st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in the North America is approaching 10% and is increasing by 5% each year.The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Spread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, by straining the Region’s economies and health systems.Prevalence of diabetes is increasing in the European Region hasreached 10-12% of the population in some of the States. This increase is strongly associated with increasing trends towards overweight and obesity, unhealthy diets, physical inactivity and socioeconomic disadvantage. This trend is significantly increasing the prevalence of diabetic Neuropathy as well.

Market key players

Some of the key players include Daiichi Sankyo Company, Eli Lilly and Company, Johnson & Johnson Services, Novartis AG, Pfizer Inc, Grunenthal GmbH, ViroMed Co, Collegium Pharmaceutical, Acorda Therapeutics, Zydus Pharmaceuticals, Mallinckrodt, Macleods Pharmaceuticals Ltd, Lupin Pharmaceuticals.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Painful Diabetic Neuropathy Drugs market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Painful Diabetic Neuropathy Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Painful Diabetic Neuropathy Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Painful Diabetic Neuropathy Drugs market?
• Which is the largest regional market for Painful Diabetic Neuropathy Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Painful Diabetic Neuropathy Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Painful Diabetic Neuropathy Drugs market worldwide?